[HTML][HTML] Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism …
S Zuily, B Lefèvre, O Sanchez, OE de Vendin… - …, 2023 - thelancet.com
Background Venous thromboembolism is a major complication of coronavirus disease 2019
(COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation
may decrease the risk of venous thromboembolism COVID-19 patients. Methods In this
multicenter, randomised, open-label, phase 4, superiority trial with blinded adjudication of
outcomes, we randomly assigned adult patients hospitalised in 20 French centers and
presenting with acute respiratory SARS-CoV-2. Eligible patients were randomly assigned (1 …
(COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation
may decrease the risk of venous thromboembolism COVID-19 patients. Methods In this
multicenter, randomised, open-label, phase 4, superiority trial with blinded adjudication of
outcomes, we randomly assigned adult patients hospitalised in 20 French centers and
presenting with acute respiratory SARS-CoV-2. Eligible patients were randomly assigned (1 …
[PDF][PDF] Effect of weight-adjusted intermediate-dose versusfixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism …
F Center - 2023 - factuel.univ-lorraine.fr
Background Venous thromboembolism is a major complication of coronavirus disease 2019
(COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation
may decrease the risk of venous thromboembolism COVID-19 patients. Methods In this
multicenter, randomised, open-label, phase 4, superiority trial with blinded adjudication of
outcomes, we randomly assigned adult patients hospitalised in 20 French centers and
presenting with acute respiratory SARS-CoV-2. Eligible patients were randomly assigned (1 …
(COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation
may decrease the risk of venous thromboembolism COVID-19 patients. Methods In this
multicenter, randomised, open-label, phase 4, superiority trial with blinded adjudication of
outcomes, we randomly assigned adult patients hospitalised in 20 French centers and
presenting with acute respiratory SARS-CoV-2. Eligible patients were randomly assigned (1 …
以上显示的是最相近的搜索结果。 查看全部搜索结果